Anlotinib Combined With mXELIRI as Second-line Treatment of Advanced Colorectal Cancer

NCT05035914 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

94

Enrollment

OTHER

Sponsor class

Conditions

Advanced Colorectal Cancer

Interventions

DRUG: Anlotinib Hydrochloride

Sponsor

Guangzhou University of Traditional Chinese Medicine

Collaborators

[object Object]